Systemic amyloidosis is a fatal disorder caused by pathological extracellular deposits of amyloid fibrils that are always coated with the normal plasma protein, serum amyloid P component (SAP). The small-molecule drug, miridesap, [(R)-1-[6-[(R)-2-carboxy-pyrrolidin-1-yl]-6-oxo-hexanoyl]pyrrolidine-2-carboxylic acid (CPHPC)] depletes circulating SAP but leaves some SAP in amyloid deposits. This residual SAP is a specific target for dezamizumab, a fully humanized monoclonal IgG1 anti-SAP antibody that triggers immunotherapeutic clearance of amyloid. We report the safety, pharmacokinetics, and dose-response effects of up to three cycles of miridesap followed by dezamizumab in 23 adult subjects with systemic amyloidosis (ClinicalTrials.gov identifier: NCT01777243). Amyloid load was measured scintigraphically by amyloid-specific radioligand binding of 123 I-labeled SAP or of 99m Tc-3,3-diphosphono-1,2-propanodicarboxylic acid. Organ extracellular volume was measured by equilibrium magnetic resonance imaging and liver stiffness by transient elastography. The treatment was well tolerated with the main adverse event being self-limiting early onset rashes after higher antibody doses related to whole body amyloid load. Progressive dose-related clearance of hepatic amyloid was associated with improved liver function tests.
INTRODUCTION
The extracellular accumulation of amyloid fibrils disrupts the archi tecture and function of affected tissues and organs in systemic am yloidosis, causing fatal disease (1) . Systemic amyloid deposits usually do not elicit inflammation or the physiological phagocytic mecha nisms that normally clear extracellular protein and cellular debris. Current management of systemic amyloidosis comprises support for damaged amyloidotic organs, coupled with attempts to reduce produc tion of amyloidogenic proteins. Even if fibril precursor abundance is sufficiently reduced, thereby arresting new amyloid accumulation, existing amyloid is cleared slowly and variably. Efforts to develop tar geted immunotherapeutic clearance of amyloid are therefore under way (2, 3) .
Human serum amyloid P component (SAP) from the plasma is present in all human amyloid deposits due to its avid but reversible bind ing to amyloid fibrils of all types (4). Our smallmolecule drug, miridesap [(R)1[6[(R)2carboxypyrrolidin1yl]6oxohexanoyl]pyrrolidine 2carboxylic acid], previously known as CPHPC, swiftly depletes circulating SAP (5) but leaves some SAP in amyloid deposits (6) . The residual SAP acts as a specific antigen target for therapeutic anti SAP antibodies that can bind to it and thereby trigger amyloid re moval (2, 3) . Plasma SAP depletion by miridesap is essential before antiSAP antibody administration to avoid formation of potentially proinflammatory circulating immune complexes. In humanized mu rine models, binding of antiSAP antibodies to amyloid activates the classical complement pathway and opsonizes the deposits with fixed complement C3, attracting and engaging macrophages that fuse into multinucleated giant cells uniquely able to surround, engulf, and destroy large complement opsonized objects (2, 7) .
We have recently reported safety and clinical proofofconcept re sults for miridesap followed by the fully humanized monoclonal antihuman SAP antibody, dezamizumab, in patients with different forms of systemic amyloidosis, including the following types: mono clonal immunoglobulin light chain (AL), reactive systemic amyloid A protein (AA), apolipoprotein AI (AApoAI), and fibrinogen A -chain (AFib). (3) . Infusion of antiSAP antibody triggered tran sient early inflammatory cytokine production and an acute phase response, followed by substantial plasma C3 depletion, but there was no new or increased renal or other organ dysfunction (3) . Am yloid clearance from the liver was associated with improved liver function tests (3) . However, maximal removal of amyloid from all or gans and tissues, which will be required for optimal clinical efficacy, was not achieved with just a single dose of antiSAP antibody. Here, we investigated the safety, tolerability, and efficacy of up to three cycles of treatment with miridesap followed by dezamizumab in 23 adult subjects with systemic amyloidosis (15 participated in the previous study, whereas 8 were new subjects).
12 with AL, 5 with AFib, 3 with transthyretin type (ATTR), 2 with AA, and 1 with AApoAI. Their demographic features, amyloid dis tribution and load, dezamizumab doses, and rationale thereof, are shown in table S1. Fifteen of the subjects had previously received a single treatment with miridesap followed by dezamizumab in the first part of the trial, designated part A, which has been reported else where (3), and eight additional subjects were newly recruited for part B. Among 48 total treatments administered to the 23 trial subjects, each with completed followup, 8 subjects received 1 treatment, 5 subjects received 2 treatments, and 10 subjects received 3 treatments.
There were no deaths during the study, no withdrawals during treat ment sessions, and no signs of organ toxicity. Injection of miridesap caused mild, transient, nontreatment limiting, local pain and occa sional erythema on four occasions, and there were 11 mild adverse events related to intravenous catheter insertion. There were also three serious adverse events. Subject 008 became hypotensive immediately after dezamizumab infusion and recovered but then had tachycardia with blood pressure around 90/60 mmHg about 4 hours later due to insufficient fluid replacement. A temporary increase in serum cre atinine concentration thereafter had returned to baseline at day 21. Subject 021 developed an erythema multiformlike rash, starting with in 24 hours of dezamizumab infusion and resolving gradually with out sequelae after 60mg oral prednisolone. Subject 018, with a history of episodic atrial fibrillation, had a spontaneously resolving episode of fast atrial fibrillation 27 days after dezamizumab infusion that was not considered related to study treatment.
Doserelated infusion reactions to dezamizumab consisted of one or more of the following: headache, flushing, feeling hot or cold, chest discomfort, chills, facial, orbital, and peripheral edema, nausea, vomit ing, diarrhea, fatigue, tachycardia, presyncope, and hypotension. None were reported at ≤650 mg in part B of the trial, but they occurred in 20% of patients receiving 1000 to 1200 mg and 50% of patients receiv ing 2000 mg. However, although not formally comprising an infusion reaction, some of these symptoms were reported within 24 hours of dezamizumab administration after 50% of doses at ≤650 mg, 67% of doses at 1000 to 1200 mg, and 75% of doses at 2000 mg. Slowing and interrupting the infusion was helpful and, together with premedication with hydrocortisone and antihistamine, enabled dezamizumab dosing up to 2000 mg in subjects with heavy amyloid loads and 1200 mg in those with small or moderate amyloid loads. In cardiac amyloidosis, dezamizumab administration split over 2 days caused no adverse car diac events.
Twenty two of 38 recipients of ≥600 mg of dezamizumab devel oped mild or moderate urticarial or macular rashes, usually within 24 to 36 hours, but there were no associated systemic symptoms, signs, or related test results, or any mucosal involvement. Urticaria responded well to antihistamines. Macular lesions were more persistent but re solved spontaneously without sequelae. Rash incidence generally in creased with increasing dezamizumab dose and was most common in subjects with a small or moderate amyloid load given higher doses that produced the highest peak plasma concentrations of dezamizumab. The rash recurred on repeat dezamizumab administration but was not necessarily more severe. Two skin biopsies were obtained. One showed active leukocytoclastic vasculitis but neither fibrinoid change or necrosis nor detectable immune complexes, immunoglobulin, or complement deposition. The other skin biopsy showed only nonspecific changes. The rash appearance within 48 hours of dezamizumab in fusion, rapidly peaking in severity, corresponded with the transient peak circulating concentration of the antibody and, together with the mild vasculitic histology without deposited immunoreactants, sug gested that circulating proinflammatory complexes or aggregates de rived from dezamizumab might be responsible. Dividing the planned dezamizumab infusion over 2 days enabled the second portion of the dose to be omitted in two subjects who developed a rash soon after the first exposure.
No other adverse effects were attributable to dezamizumab treat ment. The acute phase response and complement consumption that always preceded amyloid clearance were not associated with any organ dysfunction. Batteryoperated, portable, continuous electrocardiogra phy (EKG) recordings (Holter monitoring) showed no clinically sig nificant abnormalities. No urine sediment abnormalities were seen, and renal function was stable in all subjects, except for subject 008 as noted above.
Pharmacokinetics of miridesap and dezamizumab in patients with systemic amyloidosis
Circulating miridesap concentrations were consistent with previous clinical miridesap studies (5, 6, 8) . The regimen reduced baseline plasma SAP concentrations in all subjects to the target value of <2 mg/liter before dezamizumab was administered. Plasma SAP values had returned to the reference range at day 42.
In subjects with a heavy amyloid load, including hepatic amyloi dosis, the circulating dezamizumab concentration typically fell to <50 g/ml within 24 hours, even after the 2000mg dose. With small to moderate amyloid loads, without liver involvement, the 24hour concentration was about 150 g/ml, falling to <50 g/ml by 72 hours. After reduction of hepatic amyloid load by previous dezamizumab treatment, clearance of a subsequent antibody dose was slower, consist ent with the rate depending on targetspecific binding to amyloid associated SAP (Fig. 1) . Progressive amyloid removal in patients treated with miridesap followed by dezamizumab In the first part of the trial (part A), single doses of 246 to 650 mg of dezamizumab substantially cleared hepatic amyloid in five subjects with moderate or heavy liver load, leading to improved liver func tion tests, but amyloid removal was generally not detected in those with the heaviest liver and wholebody amyloid loads (3). In the second part of the trial (part B), which is reported in this study, there was evidence of liver amyloid reduction in some subjects who received 1000 to 1200 mg of dezamizumab but not in other subjects with the heaviest load. However, a 2000mg dose reduced amyloid load in the liver and/or spleen in five of seven subjects who received it, confirmed by 123 Ilabeled SAP scintigraphy (Fig. 2, A and B, and Table 1 ). The proportions of 123 ISAP tracer retained in the liver at 24 hours, corresponding to the Fig. 2A images, were 76.0% pretreat ment, 58.5% after the first dose, and 20.0% after the second dose. The exceptions were AL subject 011, whose clone relapsed causing new amyloid accumulation, and subject 019 who only received a single 2000mg dose (Table 1) . Apart from the latter patient, the amyloid load was reduced in the liver and/or other organs after one, two, or three doses of dezamizumab in the other nine participants who had liver amyloid. For example, Fig. 2B shows reduction in amy loid load in the spleen and kidneys of subject 017. The proportions of 123 ISAP tracer retained at 24 hours in the spleen and kidneys were 5.3 and 8.2% before and 3.8 and 5.7% at day 42 after treatment. Amyloid clearance was always preceded by plasma C3 depletion during the first week after dezamizumab infusion, with the C3 concentration falling to between 23 and 87% of predose values after the 14 treatments in these nine subjects.
Reductions in liver amyloid load detected by SAP scintigraphy were independently corroborated by equilibrium magnetic resonance imaging (MRI) measurements of the liver. The volume of the extra cellular space, where the amyloid is located, decreased toward normal in all cases. However, liver stiffness, which is markedly increased by amyloid, was the most sensitive marker for hepatic amyloid. Stiffness initially increased in some subjects (Fig. 3A) , consistent with the mas sive early infiltration of macrophages into amyloid deposits seen in the mouse model (2). However, liver stiffness then fell substantially (Fig. 3A) , consistent with amyloid clearance and the accompanying resolu tion of the cellular infiltrate reported in that animal model (2) .
Subjects 011 and 013 with AL amyloidosis, who suffered clonal re lapses after receiving their antibody dose in part A, and AL subject 014 who relapsed after a second dose in part B, accumulated additional amyloid between dosing sessions. In subject 109, with hereditary AApoAI amyloidosis and continuous production of amyloidogenic apoliprotein AI, there was evidence of amyloid removal after each dose, followed by some amyloid reaccumulation. Nevertheless, liver function was closer to normal after the third treatment compared to the original baseline (Table 1) .
Reduction in renal amyloid in patients treated with miridesap followed by dezamizumab Reduction in renal amyloid was observed in 7 of 11 subjects with renal amyloid detected by SAP scintigraphy (five with AFib and one each with AL and AA amyloidosis), generally, those treated with higher doses of dezamizumab. SAP scintigraphy showed renal amyloid re duction in zero of six subjects after <600 mg of dezamizumab, two of six (33%) after 600 to 650 mg, and five of six (83%) after 1200 mg ( Fig. 2B and table S1 ). Renal amyloid clearance was only seen in the AL case, subject 013, after a first dose of dezamizumab had cleared this patient's hepatic amyloid. The AFib patients had small to mod erate wholebody amyloid loads with no detectable liver amyloid. Renal function, serum creatinine and urea concentrations, and uri nary protein excretion were unchanged in all subjects up to day 42, the end of the protocol followup, similar to what we previously docu mented for subjects in part A, the initial phase of the trial (3).
Preliminary safety data in patients with cardiac amyloidosis
Patients with clinical cardiac amyloidosis were specifically excluded in part A for safety reasons (3). After establishing additional safety information in part B, three subjects with AL and three with ATTR cardiac amyloidosis were enrolled for preliminary assessment (Table 2) . No actual infusion reactions occurred, but there were some modest sys temic symptoms. Crucially, there were no new arrhythmias, no increase in circulating troponin T or creatine kinase concentrations, and no change in exist ing cardiac abnormalities. Nevertheless, on day 1 after antibody dosing, four of these subjects developed transient, up to fivefold, increases in the circulating concentration of Nterminal pro-Btype natriuretic pep tide (NTproBNP), lasting about 1 week (Fig. 3C) , suggesting possible engagement of the target mechanism in the heart. One subject (021) who received three antibody doses showed a reduction of 17% in left ventricular mass by cardiac MRI, greater than the coefficient of variation of the method, suggesting reduction in cardiac amyloid load (Table 2) .
DISCUSSION
Systemic amyloidosis is usually diagnosed late after the initial clinical presentation, when organ function is often already severely compromised. There have been major advances in cytotoxic chemotherapy to eliminate the B cell or plasma cell dyscrasias that cause AL, the most common type of systemic amyloidosis but, un fortunately, not all patients tolerate these toxic regimens or respond to them. About 25% of AL patients still die within the first 6 months after diagnosis and, even when there is a clonal response, regression of amyloid is slow and variable. AA amyloidosis is now rare, and the various underlying inflammatory disorders that cause it can usually be controlled, but amyloid regression is still slow and often limited. Furthermore, there are currently no approved means of reducing pro duction of transthyretin, the amyloidogenic protein in senile and he reditary ATTR amyloidosis, or the amyloidogenic proteins in other types of hereditary amyloidosis, apart from liver transplantation in AFib (9) . Thus, although reduction of amyloid fibril precursor pro teins will always be desirable, there is an urgent need for treatment that removes amyloid from the tissues. Here, we show that dezamizumab, infused after previous depletion of plasma SAP by miridesap, achieves this objective with acceptable safety. Serial doses, comprising sufficient dezamizumab in relation to each subject's amyloid load, progressively removed amyloid from the liver, spleen, and kidneys in acquired and hereditary systemic amyloidosis. Amyloid clearance from the liver was faster and more extensive than from other organs, as previously observed with sponta neous hepatic AA and AL amyloid regression in effectively treated patients (10) (11) (12) (13) . This may reflect the fact that the sinusoidal, fenestrated hepatic capillary endothelium allows unhindered access of antibodies and complement proteins from the blood to the extracellular space where the amyloid deposits are located. Although splenic capillaries also have sinusoidal endothelium, both spontaneous amyloid regres sion and amyloid clearance by miridesap plus dezamizumab are slower in the spleen, so there may be other factors, such as availability of appropriate macrophage populations. Amyloid clearance from the heart, kidneys, and other organs with tight junction capillary endothelium may also be slower. Classical complement pathway activation, which is required in the mouse model to engage macrophages and enable amyloid removal (2), requires a multimeric assembly of bound antibody molecules (14) . The effective dezamizumab doses observed in this study were consistent with the requirement to form these assemblies on the amounts of target SAP available in each individual's amyloid, and only dezamizumab doses that triggered plasma C3 depletion produced detectable amyloid clearance. However, regardless of the mechanism, our results in dicate that (i) repeated, sufficient doses of dezamizumab should sub stantially clear amyloid of all types, and (ii) repeated treatments will be required if amyloid accumulation continues when amyloidogenic fibril precursor production cannot be controlled.
Clearance of amyloid from the liver was associated with improved liver function, firmly establishing the relationship between the pres ence and amount of amyloid and the pathogenesis of organ dysfunc tion. There was no change in proteinuria or renal function through the 6week study followup; additional dosing and longer followup will be required to ascertain preservation or restoration of renal func tion. Encouraging safety and tolerability data were also obtained in the preliminary study of cardiac AL and ATTR amyloidosis. There was no evidence of myocardial damage, but early transient increases in plasma NTproBNP concentration after dezamizumab administra tion suggested that the antibody may be initiating the mechanism for potential amyloid clearance in the heart. A forthcoming larger study of serial antiSAP dosing at regular and closer intervals will seek to extend safety and establish efficacy in cardiac amyloidosis, which is the ma jor single cause of morbidity and mortality.
No direct adverse effect of dezamizumab on organ function was de tected but, as previously reported for part A, systemic infusion reac tions to effective doses were universal. They were substantially reduced by antihistamine and hydrocortisone premedication and were fur ther mitigated by divided slow infusion of larger total antibody doses, enabling use of up to the 2000mg maximum dose. Nevertheless, total doses of >600 mg caused pleomorphic urticarial and macular skin rashes in most recipients, with the time course suggesting causation by circulating proinflammatory materials derived from dezamizumab. However, the identified and potential risks of the intervention are considered manageable, and thus acceptable, in relation to the de monstrable clinical benefits of removing amyloid from vital organs.
There are several limitations to our study. Only 23 subjects have been treated hitherto, so that the scope and scale of potential adverse reactions, especially to larger and repeated doses of dezamizumab, cannot yet be reliably estimated. Despite unequivocal evidence of re duction in renal amyloid load, effects on proteinuria and preserva tion of renal function will require a longer followup than the 6 weeks of the present protocol. Other than preliminary examination of safety in the six cardiac amyloidosis patients reported in this study, the use of miridesap and dezamizumab in subjects with heart involvement will be explored in our forthcoming phase 2 trial.
Clinical trials in AL amyloidosis of two different antiamyloid anti bodies, NEOD001 (Prothena) (15) and 111F4 (Columbia) (16) , have reported improvements in some biochemical markers of cardiac func tion but did not evaluate amyloid removal. NEOD001 does not elicit any systemic reaction and, in contrast to the rapid amyloid load related clearance of dezamizumab, the 13 to 16day plasma halflife of NEOD001 approaches that of free immunoglobulin G (15) . Infu sion of 111F4 produces systemic reactions and rashes and the anti body demonstrably bound to amyloid in 9 of 18 reported AL cases (17) . Further observations are required on amyloid clearance and the clinical effects produced by each of these antibodies and by dezamizumab.
MATERIALS AND METHODS

Study design
The two center [Quintiles and GlaxoSmithKline (GSK) Clinical Unit], openlabel, nonrandomized, first in human study of the fully human ized monoclonal IgG1 antiSAP antibody (GSK2398852, dezamizumab) administered after previous infusion of miridesap (CPHPC) was ap proved by the UK Medicines and Healthcare Products Regulatory Agency and the Berkshire "B" phase 1 accredited Research Ethics Com mittee. Each dosing session comprised visits for baseline measure ments, inpatient treatment, and scheduled outpatient assessments with a followup at 6 weeks after dezamizumab dosing for evaluation of amyloid load. Part A, an initial singledose escalation study report ed previously, established safety and proof of mechanism (3). Part B, reported in this study, adaptively extended antibody dosing, eval uating up to three treatments at intervals of at least 2 months. Some part A subjects proceeded to part B, for which additional subjects were also recruited. Patients with known cardiac amyloidosis were excluded from part A but, after the acceptable initial safety profile, were in cluded in part B, provided that there was no systolic impairment, New York Heart Association class III/IV decompensated cardiac failure, recent cardiacrelated syncope or presyncope, or circulating NTproBNP >1800 ng/liter in AL amyloidosis.
Participants
Comprehensively characterized, biopsyproven, systemic amyloidosis patients (n = 23, 11 female), aged 44 to 69 years (table S1), and un der the care of the UK National Health Service National Amyloido sis Centre at the Royal Free Campus of University College London were referred for screening. All gave written informed consent, had adequate venous access, and could tolerate the study protocol. En try to the study required compliance with stringent requirements for functional status and organ function but did not have constraints regarding previous treatment. Twelve subjects had AL amyloidosis, all of whom had completed chemotherapy with either complete or good partial responses, and all had good functional status, but three of them suffered typical clonal relapses during the study. Two sub jects had AA amyloidosis, but their underlying inflammatory con ditions were in complete remission and they, together with the remaining nine subjects with hereditary AFib, ATTR, or AApoAI amyloidosis, had received only supportive care.
Anti-SAP antibody intervention
Subjects were admitted for initial plasma SAP depletion, typically by 3 days intravenous infusion of 20mg/hour miridesap (8) , to reach the selected target of <2 mg/liter. Dezamizumab was then infused intravenously, designated as study day 1. Miridesap administration was continued by subcutaneous injection, typically for 11 days, to main tain circulating SAP depletion until plasma antiSAP antibody ac tivity had disappeared. The miridesap dose of 60 mg, three times a day, was adjusted for renal impairment, if necessary, to keep predicted exposure below preestablished protocoldefined safety limits (8) .
Premedication with 100 mg of parenteral hydrocortisone and an antihistamine substantially mitigated the otherwise doselimiting re actions caused by infusion of more than 200 mg of dezamizumab in part A, allowing administration of higher doses, and was routinely used in part B. The highest antibody dose was 1200 mg in subjects with small to moderate amyloid load and 2000 mg in those with large wholebody load involving the liver. Repeat treatment depended on toleration of, and response to previous dose(s), and subject availability to comply with the protocol. Each treatment was a discrete event with a minimum interval between doses of 2 months, enabling completion of followup and evaluation of response (interval range, 4 to 19 months for part A subjects in part B; and 2 to 3 months for part B-only participants). Table S1 shows each dezamizumab dose and its rationale. Dose re sponse was initially explored in part A subjects who had shown evi dence of hepatic amyloid removal. The decision to administer second or third doses was based on tolerability and response to the previous dose and subject availability, given the substantial time commitment. Each treatment was a discrete event and the interval between doses was variable, ranging from 5 to 19 months between first and second treatments in the part A subjects and 2 to 5 months in the part B-only participants.
Global dosing strategy and individual subject dosing rationale
Reduction in hepatic amyloid was observed in five subjects in part A (subjects 007, 008, 009, 011, and 014), all with AL amyloidosis and a large liver amyloid load, who were the first to receive a second treat ment in part B. This reduced the amyloid load, shown by SAP scinti g raphy, in the spleen of subject 008 and liver of subject 014; liver stiffness was reduced in subject 009. There was no SAP scintigraphy change in the liver in subjects 007 and 011, but liver stiffness was reduced in subject 007. Subject 011 suffered a clonal relapse after the initial treatment in part A, which persisted throughout part B. Sub jects 009 and 011 had infusion reactions, subject 014 developed a moderate rash, and subject 008 had a serious adverse event: hypo tension during dezamizumab infusion leading to a temporary rise in creatinine concentration. After this event, routine premedication with 100mg hydrocortisone and a nonselective antihistamine was administered to all subjects before each dezamizumab dose.
In part A, reduction of renal amyloid was observed in subject 012 who had no liver involvement. To determine, in part B, whether the treatment could remove renal amyloid, we studied patients with AFib amyloidosis, which always involves the kidneys but typically has a small to moderate wholebody amyloid load. AL amyloidosis com monly affects the kidneys, but evaluation is complicated by extensive multisystem involvement. Subject 005, who had received only 78 mg of dezamizumab early in part A, was scheduled to receive 600 mg in part B, but the infusion was stopped as a precautionary measure at 330 mg, because subject 008, being treated at the same time, became hypo tensive after dezamizumab infusion. Renal amyloid was not reduced in subject 005 after this dose or in subject 004 after 600 mg, but the load was reduced in both cases after a subsequent dose of 1200 mg. Renal amyloid load was also reduced after 1200 mg of dezamizumab in each of the other AFib subjects, 002, 006, and 017.
Dezamizumab doses of 1000 or 1200 mg had little effect on the hepatic amyloid load in subjects 007, 010, 011, 015, and 016 with AL amyloidosis and 009 with AApoAI type, all of whom had a large liver and wholebody amyloid load. However, a subsequent 2000mg dose reduced the liver and/or spleen amyloid in all except subject 011 who was in clonal relapse. Subject 019, also with a very heavy liver and wholebody AL amyloid load, received 2000mg dezamizumab as the first dose, but no amyloid reduction was detected and the subject was unable to receive a second dose before the study closed.
Subjects with known cardiac amyloidosis were excluded from part A, but after amyloid clearance from multiple organs with acceptable safety and tolerability during part B, protocol amendment allowed enrolment of six subjects with mild but definite cardiac involvement, three with AL and three with ATTR type, for preliminary safety assess ment. Four subjects received one treatment and two subjects received three treatments. Dezamizumab infusion was split over two consecutive days and cardiac safety was closely monitored. The study ended after treat ment of the cardiac subjects because the study objectives had been achieved, the supply of dezamizumab was exhausted, and it had become evident that serial repeated treatments, with miridesap followed by doses of dezamizumab appropriate for the amyloid load in each indi vidual, would be required to optimize amyloid clearance.
Study measures
Comprehensive hematological, biochemical, cardiac, renal, and im munological tests were performed at screening, baseline before dosing, during dezamizumab infusion, the subsequent inpatient days, and, if not still an inpatient, on study days 6, 14, and 21, with final followup on day 42, along with blood sampling for pharmacokinetic studies. Amyloid load was monitored as follows. Liver stiffness was measured by transient elastography (18, 19) at baseline and days 14 and 42. Extra cellular volumes of the heart, liver, and spleen were measured by equilibrium MRI (20) (21) (22) at baseline and day 42.
123
ISAP scintigraphy (23) with computed tomography (CT)-single photon emission CT (CT SPECT) to quantify organ retention of tracer at 24 hours (24) was per formed at baseline and day 42, when the soluble and amyloidbound SAP pools had fully reequilibrated. ATTR amyloidosis subjects underwent 99m Tc3,3diphosphono1,2propanodicarboxylic acid ( 99m TcDPD) CTSPECT scintigraphy at baseline and day 42 to quantify cardiac ATTR amyloid (25) . EKGs were monitored by Holter 24hour recordings on the first day of miridesap infusion, by telemetry during dezamizumab infusion, and by Holter on study days 1 and 3 thereafter.
Study outcomes
In addition to the primary safety outcome measure, dezamizumab pharmacokinetics, plasma miridesap and SAP concentrations, am yloid load, and organ function were monitored.
Statistical analysis
Safety and pharmacokinetic outcomes were assessed without formal hy pothesis testing. Changes in absolute values and proportional changes from baseline in the different measures of amyloid load were evaluated in relation to the reference ranges and variances of the respective tests.
SUPPLEMENTARY MATERIALS
www.sciencetranslationalmedicine.org/cgi/content/full/10/422/eaan3128/DC1 Table S1 . Demographic features of participants, amyloid type and load, dezamizumab doses administered, and dosing rationale.
